| Literature DB >> 25475098 |
Punitha Vasanthan1, Vijayendran Govindasamy, Nareshwaran Gnanasegaran, Wijenthiran Kunasekaran, Sabri Musa, Noor Hayaty Abu Kasim.
Abstract
MicroRNAs (miRNAs) are small non-coding RNAs that regulate translation of mRNA into protein and play a crucial role for almost all biological activities. However, the identification of miRNAs from mesenchymal stem cells (MSCs), especially from dental pulp, is poorly understood. In this study, dental pulp stem cells (DPSCs) were characterized in terms of their proliferation and differentiation capacity. Furthermore, 104 known mature miRNAs were profiled by using real-time PCR. Notably, we observed 19 up-regulated miRNAs and 29 significantly down-regulated miRNAs in DPSCs in comparison with bone marrow MSCs (BM-MSCs). The 19 up-regulated miRNAs were subjected to ingenuity analysis, which were composed into 25 functional networks. We have chosen top 2 functional networks, which comprised 10 miRNA (hsa-miR-516a-3p, hsa-miR-125b-1-3p, hsa-miR-221-5p, hsa-miR-7, hsa-miR-584-5p, hsa-miR-190a, hsa-miR-106a-5p, hsa-mir-376a-5p, hsa-mir-377-5p and hsa-let-7f-2-3p). Prediction of target mRNAs and associated biological pathways regulated by each of this miRNA was carried out. We paid special attention to hsa-miR-516a-3p and hsa-miR-7-5p as these miRNAs were highly expressed upon validation with qRT-PCR analysis. We further proceeded with loss-of-function analysis with these miRNAs and we observed that hsa-miR-516a-3p knockdown induced a significant increase in the expression of WNT5A. Likewise, the knockdown of hsa-miR-7-5p increased the expression of EGFR. Nevertheless, further validation revealed the role of WNT5A as an indirect target of hsa-miR-516a-3p. These results provide new insights into the dynamic role of miRNA expression in DPSCs. In conclusion, using miRNA signatures in human as a prediction tool will enable us to elucidate the biological processes occurring in DPSCs.Entities:
Keywords: gene expression; medical biotechnology; mesenchymal stem cells; signalling network
Mesh:
Substances:
Year: 2014 PMID: 25475098 PMCID: PMC4369814 DOI: 10.1111/jcmm.12381
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
Sorted Log2 (fold change) of 104 miRNA between DPSCs and BMSCs using ΔΔCts. 53.85% of ΔΔCts (56 of 104 determined assays), were between +1 and −1
| Up-regulated | Down-regulated | Between +1/−1 | |||
|---|---|---|---|---|---|
| hsa-miR-516a-3p | hsa-miR-20a* | hsa-miR-154* | hsa-miR-15b* | hsa-miR-509-3p | hsa-miR-188-5p |
| hsa-miR-7-5p | hsa-miR-659 | hsa-miR-630 | hsa-miR-138-1* | hsa-miR-601 | hsa-miR-214* |
| RNU43 | hsa-miR-126* | hsa-miR-379* | hsa-miR-149* | hsa-miR-543 | hsa-miR-432* |
| hsa-miR-526b* | hsa-miR-181a-2* | hsa-miR-335* | hsa-miR-151-3p | hsa-miR-589* | hsa-miR-130b* |
| hsa-miR-376a* | hsa-miR-801 | hsa-miR-923 | hsa-miR-19b-1* | hsa-miR-625* | RNU48 |
| hsa-let-7f-2-3p | hsa-miR-34b* | hsa-miR-550 | hsa-miR-27b* | hsa-miR-638 | hsa-miR-93* |
| hsa-miR-106a | hsa-miR-27a* | hsa-miR-10b* | hsa-miR-22* | hsa-miR-643 | hsa-miR-7-1* |
| hsa-miR-190a | hsa-miR-454* | hsa-miR-18a* | hsa-miR-26a-1* | hsa-miR-656 | hsa-miR-505* |
| hsa-miR-378 | hsa-miR-513-3p | hsa-miR-15a* | hsa-miR-26b* | hsa-miR-769-5p | hsa-miR-181a* |
| hsa-miR-125b-1* | hsa-miR-29c* | hsa-miR-500* | hsa-miR-30e* | hsa-miR-877 | hsa-miR-222* |
| hsa-miR-629* | hsa-miR-16-1* | hsa-miR-30a* | hsa-miR-942 | hsa-miR-135a* | |
| hsa-miR-939 | hsa-miR-941 | hsa-miR-30d | RNU24 | hsa-miR-493* | |
| hsa-miR-377* | hsa-miR-432 | hsa-miR-30e | RNU44 | hsa-miR-145* | |
| hsa-miR-565 | hsa-miR-136* | hsa-miR-34a* | RNU6B | hsa-miR-875-5p | |
| hsa-miR-766 | hsa-miR-661 | hsa-miR-411* | hsa-miR-768-3p | hsa-miR-30d* | |
| hsa-miR-148b* | hsa-miR-99a* | hsa-miR-409-3p | hsa-miR-373* | hsa-miR-550* | |
| hsa-miR-221* | hsa-miR-520c-3p | hsa-miR-424* | hsa-let-7i* | hsa-miR-21* | |
| hsa-miR-584 | hsa-miR-99b* | hsa-miR-425* | hsa-miR-100* | hsa-miR-760 | |
| hsa-miR-564 | hsa-miR-206 | hsa-miR-770-5p | hsa-miR-30a | ||
Fig 1miRNAs manifestation in DPSCs compared with BM-MSCs. (A) The log2 of RQ value was used to plot the relative fold change. Y-axis: log2 RQ, X-axis: miRNA. Sorted Log2 RQ shows 29 miRNAs with decreased expression and 19 with increased expression in DPSCs. The most significant difference was seen in hsa-miR-500* with decreased expression, and hsa-miR-516a-3p with increased expression [RQ + 2−ΔΔCt, ΔΔCt + ΔCt (DPSCs) − ΔCt (BM-MSCs), ΔCt + Ct (target miRNA) − Ct (endogenous control)]. Venn diagram showing the number of shared and specific miRNAs for DPSCs and BM-MSCs. (B) Scatter plot and correlation analysis between DPSCs and BM-MSCs with standard correlation found to be R2 is over 76%. (C) Major functions inclined by miRNA action on putative target genes using IPA of MSCs of BM versusDP. Height of bar is determined by projected involvement of the particular pathways.
Fig 2Network 1: Schematic representation describing the interaction between 5 highly expressed miRNAs found in DPSCs with their associated target mRNAs and cellular proteins related to cancer, reproductive system disease and genetic disorder. The miRNAs are namely hsa-miR-516a-3p, hsa-miR-125b, hsa-miR-190a, hsa-miR-106a and hsa-miR-584-5p. Network was constructed by using Ingenuity software based on expression relationships described in the literature. For miRNA analysis, the colour intensities (from pink to red) were correlated with fold change intensities, in which miRNAs overexpressed in functional analysis, are indicated in red.
Top two associated network functions generated by using Ingenuity Pathway Analysis
| Network | miRNA | Abbr. | Entrez gene name | Function |
|---|---|---|---|---|
| Reproductive system disease, Cancer, Genetic disorder | miR-638 | ARID4B | AT-rich interactive domain 4B (RBP1-like) | Other |
| miR-26a-1-3p | BAMBI | BMP and activin membrane-bound | Other | |
| miR-294-5p | BMPR2 | inhibitor homologue | Kinase | |
| miR-30c-5p/miR-30c/miR-30b-5p | CTNNB1 | bone morphogenetic protein receptor, type II | Transcription | |
| miR-30a-3p/miR-30d-3p/miR-30e | CYR61 | catenin (cadherin-associated protein), | Regulator | |
| miR-26b-3p/miR-26b*/miR-26a-2-3p | HIPK3 | beta 1, 88 kD | Other | |
| miR-125b-1-3p/miR-125b-3p | MICA | cysteine-rich, angiogenic inducer, 61 | Kinase | |
| miR-190a | MYLIP | homeodomain interacting protein kinase 3 | Other | |
| miR-106a | PKD2 | MHC class I polypeptide-related sequence A | Enzyme | |
| miR-584-5p | TNF | myosin regulatory light-chain interacting | Ion channel | |
| miR-17-5p/miR-20b-5p/miR-93-5p | VEZT | protein polycystic kidney disease 2 | Cytokine | |
| miR-516a-3p/miR-516b-3p | WNT3A | (autosomal dominant) | Other | |
| WNT5A | tumour necrosis factor | Cytokine | ||
| ZBTB7A | vezatin, adherens junctions transmembrane protein | Cytokine | ||
| wingless-type MMTV integration site family, member 3A | Transcription regulator | |||
| wingless-type MMTV integration site family, member 5A | ||||
| zinc finger and BTB domain containing 7A | ||||
| Genetic disorder, Skeletal and muscular disorder, Developmental disorder | miR-543-3p/miR-543*/miR-543 | DICER1 | dicer 1, ribonuclease type III | Enzyme |
| miR-409-3p (human, mouse) | EGFR | epidermal growth factor receptor | Kinase | |
| miR-409-5p | EIF2C2 | eukaryotic translation initiation factor 2C, 2 | Translation | |
| miR-4712-5p/miR-770-5p | FOS | FBJ murine osteosarcoma viral oncogene | regulator | |
| miR-425-3p/miR-425* | IRS1 | homologue | Transcription factor | |
| miR-656 | NR0B2 | insulin receptor substrate 1 | Enzyme | |
| miR-539 | nuclear receptor subfamily 0, group B, member 2 | Ligand dependent nuclear receptor | ||
| miR-431 | ||||
| miR-495 | ||||
| miR-494 | ||||
| miR-487 | ||||
| miR-382 | ||||
| miR-7-5p/miR-7a-5p/miR-7a | ||||
| miR-221-5p/miR-221* | ||||
| miR-377-5p/miR-672-5p/miR-672 | ||||
| let-7f-2-3p | ||||
| miR-376a-5p |
Fig 3Network 2: Schematic representation describing the interaction between 5 highly expressed miRNAs found in DPSCs with their associated target mRNAs as well as cellular proteins related to genetic, developmental, skeletal and muscular disorder. The miRNAs are namely hsa-miR-7-5p, hsa-miR-221-5p, hsa-miR-377-5p, hsa-miR-376a-5p, and let-7f-2-3p. Network was constructed by using Ingenuity software based on expression relationships described in the literature. For miRNA analysis, the colour intensities (from pink to red) were correlated with fold change intensities, in which miRNAs overexpressed in functional analysis, are indicated in red.
Fig 4Validation of 10 highly expressed miRNAs in DPSCs using qRT-PCR. Generally, the higher a fold change value, the more copies are present in the specific sample. The miRNAs expression levels were calculated by using comparative cycle threshold (Ct) method. Ct values of target miRNAs were normalized in relation to U6 snRNA, which is an internal control gene. The fold change was calculated by using the equation 2−ΔΔCT.
Fig 5WNT5A is a potential hsa-miR-516a-3p target. (A) Sequence alignment of hsa-miR-516a-3p and predicted binding sites in the 3′-UTR of WNT5A (http://www.targetscan.org). (B) Quantification of WNT5A mRNA expression levels in response to the mimic and inhibitory effect of hsa-miR-516a-3p. (C) Protein level expression of the results shown in (B). Data are shown as the mean of SD values (n + 3).
Fig 6Validation of WNT5A gene as a target gene of hsa-miR-516a-3p. (A) Schematic diagram of luciferase reporter constructs for consensus hsa-miR-516a-3p target sites at the 3′-UTR region. (B) The sequence alignment of the predicted hsa-miR-516a-3p binding site in the 3′-UTR region of human WNT5A is shown with the seed target sequence (UCCUUCG). (C) Luciferase reporter vector containing hsa-miR-516a-3p target seed region of WNT5A (wild-type) or same vector without target seed region (empty vector) or same vector with deletion of the target seed region (mutant) were cotransfected with miR-516 mimics or negative control respectively. Data are representative of at least three technical experiments.
Fig 7EGFR is a potential hsa-miR-7-5p target. (A) Sequence alignment of hsa-miR-7-5p and predicted binding sites in the 3′-UTR of EGFR (http://www.targetscan.org). (B) Quantification of EGFR mRNA expression levels in response to the mimic and inhibitory effect of hsa-miR-7-5p. (C) Protein level expression of the results shown in (B). Data are shown as the mean of SD values (n + 3).